Kensei Yamaguchi
0000-0001-6887-5709
Publication & Citation Trends
Publications
0 total
Clinical significance of serum tumor marker dynamics during preoperative chemotherapy and hepatectomy for colorectal liver metastases.
Cited by 0
Semantic Scholar
Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
Cited by 0
Semantic Scholar
Prognostic impact of RAS/BRAF mutations and clinical factors in 441 patients undergoing pulmonary metastasectomy for colorectal cancer.
Cited by 0
Semantic Scholar
Prognostic value of KRAS exon 3, exon 4, and NRAS mutations in pathological stage III colon cancer.
Cited by 0
Semantic Scholar
Comparative effectiveness of trastuzumab deruxtecan versus real-world treatment in HER2-amplified advanced solid tumors detected by cell-free DNA: An exploratory analysis of the HERALD trial and GOZILA study.
Cited by 0
Semantic Scholar
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer
Cited by 0
Semantic Scholar
Abstract 3052: RK-582, a tankyrase inhibitor, attacks Wnt-driven colorectal cancer cells with short-type APC mutations and high β-catenin expression
Cited by 0
Semantic Scholar
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Cited by 0
Semantic Scholar
Research Topics
Gastric Cancer Management and Outcomes
(379)
Colorectal Cancer Treatments and Studies
(319)
Cancer Treatment and Pharmacology
(108)
Cancer Immunotherapy and Biomarkers
(100)
Gastrointestinal Tumor Research and Treatment
(100)
Affiliations
Scripps Research Institute
Toho University
House Clinic
University of Nagasaki
Kyushu University